USA

The deal collapsed after STAAR failed to secure sufficient shareholder approval during a special stockholders meeting held on January 6.

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.

This deal gives Samsung Biologics its first manufacturing site in the US and reinforces its long-term commitment to serving the North American biopharmaceutical market.

Under the new guidance, only infants whose mothers test positive for hepatitis B or whose status is unknown will automatically receive the vaccine at birth.

The study compared the drug against bendamustine plus rituximab (BR) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who had not received prior treatment and did not have 17p deletions.

These investments will focus primarily on companies developing breakthrough technologies in gastrointestinal (GI), urology, and respiratory care.

The Alabama site is part of Lilly’s USD 27 billion U.S. onshoring initiative, aimed at reinforcing domestic pharmaceutical manufacturing.